Compare GLOB & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLOB | RAPP |
|---|---|---|
| Founded | 2003 | 2022 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2015 | 2024 |
| Metric | GLOB | RAPP |
|---|---|---|
| Price | $36.24 | $30.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 14 |
| Target Price | $51.23 | ★ $63.04 |
| AVG Volume (30 Days) | ★ 820.9K | 410.4K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.08 | N/A |
| P/E Ratio | $22.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.56 | $23.75 |
| 52 Week High | $72.10 | $52.93 |
| Indicator | GLOB | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 49.85 | 27.01 |
| Support Level | $35.68 | $26.08 |
| Resistance Level | $38.88 | $31.57 |
| Average True Range (ATR) | 1.34 | 2.30 |
| MACD | 0.19 | -0.25 |
| Stochastic Oscillator | 56.82 | 12.40 |
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.